glp-1 obesity drug market news today Analogues Size, Share & Growth Drivers By 2034 Obesity GLP-1 Market Size to

As a triple agonist activating GLP-1, GIP, and glucagon receptors, it provides the most comprehensive receptor coverage available

doi:10.1210/jc.2012-1544 173

To the best of our knowledge, this meta-analysis is the first to evaluate the effects and safety of SGLT2i and GLP-1RAs as first-line therapy for T2DM with low cardiovascular risk

Jin M, Zhang S, Huang B, Li L, Liang H, Ni A, et al

Track your calories manually if needed

As discussed below, factors including which population of receptors, the receptor pharmacology, and disease state to target all require consideration in determining whether agonism or antagonism of the GIPR is appropriate